RxDoctor Payments Data

Kaitlin Zuleta

Adult Health · Greensboro, NCNPI 1659079358

Payments from drug & device makers

$2,894in general payments, 2019–2025

Across 38 payments — averaging $76.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Medtronic$192
  • AbbVie$58
  • Boston Scientific$58
  • Convatec Inc.$39
  • Sumitomo Pharma America, Inc.$31
  • plus $54 from 3 others
$280in research payments, 2019–2025

Across 1 payment — averaging $280.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$280

What the payments were for

  • Travel & lodging$1,83263%
  • Food & beverage$1,03536%
  • Education$271%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.17$2,464
Medtronic8$192
AbbVie3$58
Boston Scientific3$58
Convatec Inc.2$39
Sumitomo Pharma America, Inc.2$31
Pfizer1$24
Olympus America Inc.1$16
Avation Medical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,894 in reported general payments places this provider in the 80th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$25,401
Medicare patients
105
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron122$104,482
MyrbetriqMirabegron78$49,035
EstringEstradiol18$9,525
Trospium Chloride ErTrospium Chloride54$8,593
Estradiol129$8,455
Fosfomycin Tromethamine14$1,758
Methenamine Hippurate29$1,571
Trospium Chloride22$1,064
Clobetasol EmollientClobetasol Propionate/Emoll17$744
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst45$721
Cephalexin27$242
Fluconazole45$143
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim43$107
Oxycodone Hcl28$78
Ibuprofen26$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$31$104,482122 claims
PfizerEstring$24$9,52518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 adult health providers in North Carolina.

Other adult health in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →